Clinical Cancer Research Grants Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dong, Y.
Right arrow Articles by Clements, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dong, Y.
Right arrow Articles by Clements, J. A.
Clinical Cancer Research Vol. 7, 2363-2371, August 2001
© 2001 American Association for Cancer Research


Regular Articles

Human Kallikrein 4 (KLK4) Is Highly Expressed in Serous Ovarian Carcinomas1

Ying Dong, Aneel Kaushal, Loan Bui, Simon Chu, Peter J. Fuller, Jim Nicklin, Hemamali Samaratunga and Judith A. Clements2

Centre of Molecular Biotechnology, School of Life Sciences, Queensland University of Technology, Brisbane, Queensland 4001, Australia [Y. D., A. K., L. B., J. A. C.]; Prince Henry’s Institute of Medical Research, Clayton, 3168 Australia [S. C., P. J. F.]; Department of Obstetrics and Gynecology, Royal Women’s Hospital, Herston, Brisbane, Australia [J. N.]; and Department of Pathology, Royal Brisbane Hospital, Herston, Brisbane, 4029 Australia [H. S.]

Previous studies indicated that a new member of the human kallikrein (KLK) gene family, KLK4, was expressed in prostate, breast, and endometrial carcinoma cell lines and may have potential as a tumor marker. The aim of this study was to examine the expression of KLK4 in the normal ovary and ovarian tumors of different histology, stage, and differentiation and to determine its association with ovarian tumor progression. Using reverse transcription-PCR, Southern blot, and densitometry analyses, we found the level of KLK4 expression was higher in late stage serous (SER) epithelial-derived ovarian carcinomas than in normal ovaries, mucinous epithelial tumors, and granulosa cell tumors. KLK4 was highly expressed in all of the SER ovarian carcinoma cell lines (eight of eight), SER epithelial carcinomas (11 of 11), and two adenomas, whereas it was expressed at a lower level (or not at all) in normal ovaries (four of six), mucinous epithelial tumors (three of four), endometrioid carcinomas (four of five), clear cell carcinomas (two of three), or granulosa cell tumors (three of six). Of particular interest, KLK4 mRNA variants were detected in SER ovarian carcinoma cell lines and primary cultured ovarian tumor cells, but they were not present in normal ovaries. In situ hybridization analysis showed that KLK4 mRNA transcripts are localized to adenocarcinoma cells of ovarian tumor tissues. Similarly, immunohistochemical staining of ovarian carcinoma sections showed immunoreactivity to KLK4 protein product (hK4) antipeptide antibodies. In addition, intracellular hK4 levels, as detected on Western blot analysis, were induced by 100 nM estrogen treatment of the estrogen receptor positive ovarian carcinoma cell line OVCAR-3, >8–24 h. Our results show that the level of KLK4 expression and expression of KLK4 mRNA variants are associated with progression of ovarian cancer, particularly late stage SER adenocarcinomas. Moreover, hK4 may be a candidate marker for the diagnosis and/or monitoring of ovarian epithelial carcinomas.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
J. P. Simmer, Y. Hu, R. Lertlam, Y. Yamakoshi, and J. C.-C. Hu
Hypomaturation Enamel Defects in Klk4 Knockout/LacZ Knockin Mice
J. Biol. Chem., July 10, 2009; 284(28): 19110 - 19121.
[Abstract] [Full Text] [PDF]


Home page
JDRHome page
C.E. Tye, C.T. Pham, J.P. Simmer, and J.D. Bartlett
DPPI May Activate KLK4 during Enamel Formation
Journal of Dental Research, April 1, 2009; 88(4): 323 - 327.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
J. Lai, S. A. Myers, M. G. Lawrence, D. M. Odorico, and J. A. Clements
Direct Progesterone Receptor and Indirect Androgen Receptor Interactions with the Kallikrein-Related Peptidase 4 Gene Promoter in Breast and Prostate Cancer
Mol. Cancer Res., January 1, 2009; 7(1): 129 - 141.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clin. Chem., December 1, 2008; 54(12): e11 - e79.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Planque, L. Li, Y. Zheng, A. Soosaipillai, K. Reckamp, D. Chia, E. P. Diamandis, and L. Goodglick
A Multiparametric Serum Kallikrein Panel for Diagnosis of Non-Small Cell Lung Carcinoma
Clin. Cancer Res., March 1, 2008; 14(5): 1355 - 1362.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Zheng, D. Katsaros, S. J.C. Shan, I. R. de la Longrais, M. Porpiglia, A. Scorilas, N. W. Kim, R. L. Wolfert, I. Simon, L. Li, et al.
A Multiparametric Panel for Ovarian Cancer Diagnosis, Prognosis, and Response to Chemotherapy
Clin. Cancer Res., December 1, 2007; 13(23): 6984 - 6992.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. I. Klokk, A. Kilander, Z. Xi, H. Waehre, B. Risberg, H. E. Danielsen, and F. Saatcioglu
Kallikrein 4 Is a Proliferative Factor that Is Overexpressed in Prostate Cancer
Cancer Res., June 1, 2007; 67(11): 5221 - 5230.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
Y Dong, L T Bui, D M Odorico, O L Tan, S A Myers, H Samaratunga, R A Gardiner, and J A Clements
Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms
Endocr. Relat. Cancer, December 1, 2005; 12(4): 875 - 889.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
C. V. Obiezu, S. J.C. Shan, A. Soosaipillai, L.-Y. Luo, L. Grass, G. Sotiropoulou, C. D. Petraki, P. A. Papanastasiou, M. A. Levesque, and E. P. Diamandis
Human Kallikrein 4: Quantitative Study in Tissues and Evidence for Its Secretion into Biological Fluids
Clin. Chem., August 1, 2005; 51(8): 1432 - 1442.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. D. Santin, E. P. Diamandis, S. Bellone, A. Soosaipillai, S. Cane, M. Palmieri, A. Burnett, J. J. Roman, and S. Pecorelli
Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer
Clin. Cancer Res., May 1, 2005; 11(9): 3320 - 3325.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
I. P. Michael, L. Kurlender, N. Memari, G. M. Yousef, D. Du, L. Grass, C. Stephan, K. Jung, and E. P. Diamandis
Intron Retention: A Common Splicing Event within the Human Kallikrein Gene Family
Clin. Chem., March 1, 2005; 51(3): 506 - 515.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. P. Simmer, J. D. Bartlett, and F. Saatcioglu
Kallikrein 4 Is a Secreted Protein
Cancer Res., November 15, 2004; 64(22): 8481 - 8483.
[Full Text] [PDF]


Home page
Mol Cancer ResHome page
C. A. Borgono, I. P. Michael, and E. P. Diamandis
Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer
Mol. Cancer Res., May 1, 2004; 2(5): 257 - 280.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
L. J. Spicer
Proteolytic Degradation of Insulin-Like Growth Factor Binding Proteins by Ovarian Follicles: A Control Mechanism for Selection of Dominant Follicles
Biol Reprod, May 1, 2004; 70(5): 1223 - 1230.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Shigemasa, L. Gu, H. Tanimoto, T. J. O'Brien, and K. Ohama
Human Kallikrein Gene 11 (KLK11) mRNA Overexpression Is Associated with Poor Prognosis in Patients with Epithelial Ovarian Cancer
Clin. Cancer Res., April 15, 2004; 10(8): 2766 - 2770.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z. Xi, T. I. Klokk, K. Korkmaz, P. Kurys, C. Elbi, B. Risberg, H. Danielsen, M. Loda, and F. Saatcioglu
Kallikrein 4 is a Predominantly Nuclear Protein and Is Overexpressed in Prostate Cancer
Cancer Res., April 1, 2004; 64(7): 2365 - 2370.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Scorilas, C. A. Borgono, N. Harbeck, J. Dorn, B. Schmalfeldt, M. Schmitt, and E. P. Diamandis
Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic Marker
J. Clin. Oncol., February 15, 2004; 22(4): 678 - 685.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. M. Yousef, A. Scorilas, D. Katsaros, S. Fracchioli, L. Iskander, C. Borgono, I. A. Rigault de la Longrais, M. Puopolo, M. Massobrio, and E. P. Diamandis
Prognostic Value of the Human Kallikrein Gene 15 Expression in Ovarian Cancer
J. Clin. Oncol., August 15, 2003; 21(16): 3119 - 3126.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. M. Yousef, M.-E. Polymeris, L. Grass, A. Soosaipillai, P.-C. Chan, A. Scorilas, C. Borgono, N. Harbeck, B. Schmalfeldt, J. Dorn, et al.
Human Kallikrein 5: A Potential Novel Serum Biomarker for Breast and Ovarian Cancer
Cancer Res., July 15, 2003; 63(14): 3958 - 3965.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. M. Yousef, M.-E. Polymeris, G. M. Yacoub, A. Scorilas, A. Soosaipillai, C. Popalis, S. Fracchioli, D. Katsaros, and E. P. Diamandis
Parallel Overexpression of Seven Kallikrein Genes in Ovarian Cancer
Cancer Res., May 1, 2003; 63(9): 2223 - 2227.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Dong, A. Kaushal, M. Brattsand, J. Nicklin, and J. A. Clements
Differential Splicing of KLK5 and KLK7 in Epithelial Ovarian Cancer Produces Novel Variants with Potential as Cancer Biomarkers
Clin. Cancer Res., May 1, 2003; 9(5): 1710 - 1720.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. P. Diamandis, A. Scorilas, S. Fracchioli, M. van Gramberen, H. de Bruijn, A. Henrik, A. Soosaipillai, L. Grass, G. M. Yousef, U.-H. Stenman, et al.
Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma
J. Clin. Oncol., March 15, 2003; 21(6): 1035 - 1043.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
C. D. Petraki, V. N. Karavana, L.-Y. Luo, and E. P. Diamandis
Human Kallikrein 10 Expression in Normal Tissues by Immunohistochemistry
J. Histochem. Cytochem., September 1, 2002; 50(9): 1247 - 1261.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
E. P. Diamandis and G. M. Yousef
Human Tissue Kallikreins: A Family of New Cancer Biomarkers
Clin. Chem., August 1, 2002; 48(8): 1198 - 1205.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
C. V. Obiezu, A. Soosaipillai, K. Jung, C. Stephan, A. Scorilas, D. H. C. Howarth, and E. P. Diamandis
Detection of Human Kallikrein 4 in Healthy and Cancerous Prostatic Tissues by Immunofluorometry and Immunohistochemistry
Clin. Chem., August 1, 2002; 48(8): 1232 - 1240.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. A. Hural, R. S. Friedman, A. McNabb, S. S. Steen, R. A. Henderson, and M. Kalos
Identification of Naturally Processed CD4 T Cell Epitopes from the Prostate-Specific Antigen Kallikrein 4 Using Peptide-Based In Vitro Stimulation
J. Immunol., July 1, 2002; 169(1): 557 - 565.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.